Literature DB >> 6290435

Hemodynamic response to converting enzyme inhibition at rest and exercise in humans.

R Fagard, P Lijnen, L Vanhees, A Amery.   

Abstract

The response of the systemic circulation to acute inhibition of the converting enzyme with 25 mg of oral Captopril (Squibb) was studied in six normal sodium-replete male volunteers at rest and during exercise, together with its effects on exercise capacity for graded uninterrupted exercise. In recumbent subjects at rest Captopril did not affect arterial pressure or heart rate, and plasma renin activity rose 2.5-fold (P less than 0.05). In subjects in the sitting position, at rest and during exercise until exhaustion, Captopril reduced mean brachial intra-arterial pressure by an average of 7 Torr in comparison to placebo (P less than 0.001). Captopril's hypotensive effect was caused by a reduction of systemic vascular resistance (P less than 0.01), without changes of cardiac output (measured by CO2 rebreathing), heart rate, or stroke volume. Plasma renin activity was significantly higher during Captopril (P less than 0.001). Peak oxygen uptake and exercise duration were the same after administration of Captopril or placebo. The data demonstrate that the renin-angiotensin system is not involved in the homeostasis of blood pressure in supine sodium-replete humans, but has a modest role in blood pressure regulation when posture is changed from supine to upright. The orthostatic effect of Captopril is maintained during upright exercise. Furthermore the reduction of systemic vascular resistance by Captopril does not affect peak oxygen uptake.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6290435     DOI: 10.1152/jappl.1982.53.3.576

Source DB:  PubMed          Journal:  J Appl Physiol Respir Environ Exerc Physiol        ISSN: 0161-7567


  10 in total

Review 1.  Influence of antihypertensive drugs on exercise capacity.

Authors:  R Fagard; J Staessen; L Thijs; A Amery
Journal:  Drugs       Date:  1993       Impact factor: 9.546

2.  Effects of prolonged administration of the angiotensin converting enzyme inhibitor CGS 16617 in normotensive volunteers.

Authors:  G Waeber; M Burnier; M Porchet; J Nussberger; B Waeber; H R Brunner
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Influence of angiotensin II blockade during exercise in the heat.

Authors:  K D Mittleman
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

4.  Effects of angiotensin II on arterial pressure, renin and aldosterone during exercise.

Authors:  R Fagard; P Lijnen; A Amery
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1985

5.  No correlation between circulating ACE activity and VO2max or mechanical efficiency in women.

Authors:  Stephen H Day; Peter Gohlke; Sukhbir S Dhamrait; Alun G Williams
Journal:  Eur J Appl Physiol       Date:  2006-09-28       Impact factor: 3.078

6.  Exercise performance during captopril and atenolol treatment in hypertensive patients.

Authors:  M A Van Baak; F M Koene; F T Verstappen; E S Tan
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

Review 7.  Keeping pace with ACE: are ACE inhibitors and angiotensin II type 1 receptor antagonists potential doping agents?

Authors:  Pei Wang; Matthew N Fedoruk; Jim L Rupert
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

Review 8.  Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review.

Authors:  R J Cody
Journal:  Drugs       Date:  1984-08       Impact factor: 9.546

Review 9.  Comparative cardiovascular effects of drugs used for hypertension.

Authors:  M Burnier; B Waeber; J Nussberger; H R Brunner
Journal:  Drugs       Date:  1990       Impact factor: 9.546

10.  Angiotensin converting enzyme inhibition reduces cardiovascular responses to acute stress in myocardially infarcted and chronically stressed rats.

Authors:  A Cudnoch-Jedrzejewska; K Czarzasta; L Puchalska; J Dobruch; O Borowik; J Pachucki; E Szczepanska-Sadowska
Journal:  Biomed Res Int       Date:  2014-06-19       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.